ACM
ELVN icon

Aquatic Capital Management’s Enliven Therapeutics ELVN Stock Holding History

Aquatic Capital Management’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$426K Buy
+8,400
New +$357K 0.01% 841
2026
Q1 		– Sell
-27,955
Closed -$431K – 1493
2025
Q4 		$431K Buy
+27,955
New +$557K 0.01% 785

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Aquatic Capital Management's ELVN Position: Q2 2026 in Review

Aquatic Capital Management opened a new position in Enliven Therapeutics (ELVN) in Q2 2026: 8,400 shares worth $426K. The stake represents 0.01% of the portfolio and ranks #841 among its holdings. This is a return to the name: Aquatic Capital Management previously reported a position in ELVN as recently as Q4 2025.

Aquatic Capital Management first reported a position in ELVN in Q4 2025 and has held it in 2 quarters since. The position peaked at $431K in Q4 2025. 212 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Aquatic Capital Management held 8,400 shares of Enliven Therapeutics worth $426K as of Q2 2026.
  • Enliven Therapeutics was a new Aquatic Capital Management position in Q2 2026.
  • Enliven Therapeutics made up 0.01% of Aquatic Capital Management's portfolio in Q2 2026, its #841 holding.
  • Aquatic Capital Management first reported a position in Enliven Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Aquatic Capital Management's Enliven Therapeutics position peaked at $431K in Q4 2025.
  • 212 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Aquatic Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.